Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus irinotecan as second-line therapy for advanced gastric cancer
ChiCTR-OIN-17010407Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Mar 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and irinotecan in gastric cancer (GC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Objective response rate and Disease control rate. Started Mar 2017; status: recruiting.
02
Drugs
Rivoceranibirinotecan
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-OIN-17010407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-17010407.